Intellia Therapeutics (NTLA) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi
May 9, 2024 4:40 PM EDTCiti analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a Neutral rating.
The analyst comments "On the 1Q24 call, Intellia announced a new NTLA-2001 Ph3 trial in ATTR-PN (starting 2024). NTLA-2001s Ph3 MAGNITUDE... More



